Business
NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany
CAMBRIDGE, Mass, Oct. 21, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"CAMBRIDGE, Mass, Oct. 21, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (\"NeuroSense\"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in the BIO-Europe® Partnering Conference on October 24-26, 2022 in Lepzing, Germany.\n \nNeuroSense's VP Business Development, Nedira Salzman Frenkel, will meet with companies in the CNS field to explore potential collaboration and partnership opportunities, and Dr. Niva Russek Blum, VP Discovery & IP Generator will evaluate assets from institutions and companies working on neurology indications.\nProspective partners and interested parties attending BIO-Europe may request a meeting with NeuroSense by emailing: [email protected] \nAbout NeuroSense\nNeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.\nFor additional information, we invite you to visit our website and follow us on LinkedIn and Twitter.\nForward-Looking Statements\nThis press release contains \"forward-looking statements\" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \"anticipate,\" \"believe,\" \"contemplate,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"seek,\" \"may,\" \"might,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"target,\" \"aim,\" \"should,\" \"will\" \"would,\" or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are ba...